A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts

Transplant Proc. 1989 Feb;21(1 Pt 3):3004-7.

Authors

P J Henslee¹, V S Byers, C D Jennings, E Marciniak, J S Thompson, J S Macdonald, E H Romond, M J Messino, P J Scannon

Affiliation

¹ Department of Medicine, University of Kentucky Medical Center, Lexington 40536-0084.

PMID: 2650413

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Bone Marrow Transplantation* / immunology
Drug Evaluation
Graft vs Host Disease / immunology
Graft vs Host Disease / prevention & control*
Histocompatibility Testing
Humans
Immunotoxins / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
Lymphocyte Depletion*
Male
Postoperative Complications / prevention & control
Ricin / immunology
Ricin / therapeutic use*
T-Lymphocytes*

Substances

Antibodies, Monoclonal
Immunotoxins
zolimomab aritox
Ricin